Preferred Label : icatibant;
MeSH note : an antiasthmatic agent; a potent bradykinin (B2) receptor antagonist; WIN 65365 is
an L-Tic(7) stereoisomer, exhibits 2000-fold lower binding affinity than HOE-140 to
the bradykinin receptor;
CISMeF synonym : JE 049; JE049 compound; WIN 65365;
MeSH synonym : D-Arg(Hyp(3)-Thi(5)-D-Tic(7)-Oic(8))BK;
MeSH hyponym : WIN-65365; Hoechst-140; Hoechst 140; HOE-140; HOE140; JE-049; Firazyr; HOE 140; D-Arg(Hyp(3)-Thi(5)-L-Tic(7)-Oic(8))BK;
MeSH Related Number : icatibant acetate; 130308-48-4 (icatibant); 325O8467XK;
Registry Number MeSH : 130308-48-4;
Related CAS MeSH : 138614-30-9 (icatibant acetate);
related registry number list (CISMeF) : 138614-30-9 (acetate);
Is substance : O;
UNII : 7PG89G35Q7;
InChIKey : QURWXBZNHXJZBE-SKXRKSCCSA-N;
Origin ID : C065679;
UMLS CUI : C0246269;
ATC code(s)
CISMeF manual mappings
MeSH indexing information
MeSH term(s) associated for indexing
Pharmacological action(s)
Record concept(s)
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
https://www.ema.europa.eu/en/medicines/human/EPAR/icatibant-accord
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
icatibant
icatibant
drugs, generic
angioedemas, hereditary
child
adolescent
adult
injections, subcutaneous
icatibant
pregnancy
breast feeding
fertility
Bradykinin B2 Receptor Antagonists
Bradykinin B2 Receptor Antagonists
drug evaluation, preclinical
---
https://www.has-sante.fr/portail/jcms/c_2873704/fr/firazyr
https://www.has-sante.fr/portail/jcms/c_2873704/fr/firazyr-icatibant
2018
false
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
icatibant acetate
icatibant
guidelines for drug use
hereditary angioedema types I and II
adult
icatibant
bradykinin
bradykinin
---
2018
false
France
French
child
adolescent
icatibant acetate
icatibant acetate
icatibant
orphan drug production
injections, subcutaneous
icatibant
bradykinin
hereditary angioedema types I and II
acute disease
emergency treatment
treatment outcome
icatibant
evaluation of the transparency committee
---
https://www.ema.europa.eu/medicines/human/EPAR/Firazyr
2012
false
United Kingdom
English
French
syndication feed
adolescent
child
bradykinin
bradykinin
drug approval
treatment outcome
drug labeling
adult
injections, subcutaneous
pregnancy
breast feeding
bradykinin
orphan drug production
receptor, bradykinin b2
drug evaluation, preclinical
icatibant
icatibant
hereditary angioedema types I and II
icatibant
package leaflet
drug evaluation
summary of product characteristics
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=61680479
2012
France
summary of product characteristics
package leaflet
icatibant
injections
syringes
---
https://www.revmed.ch/RMS/2011/RMS-278/Allergo-immunologie.-1.-Nouveautes-dans-le-traitement-des-crises-aigues-d-angioedeme-hereditaire
2011
false
true
false
Switzerland
bradykinin
angioedemas, hereditary
receptors, bradykinin
icatibant
journal article
angioedemas, hereditary
bradykinin
---
http://www.has-sante.fr/portail/jcms/c_724464/firazyr-ct-5904
http://www.has-sante.fr/portail/jcms/c_724460/firazyr
2008
France
French
orphan drug production
receptor, bradykinin b2
bradykinin
adrenergic beta-antagonists
adult
injections, subcutaneous
treatment outcome
pharmaceutical solutions
icatibant
hereditary angioedema types I and II
icatibant
rare diseases
evaluation of the transparency committee
---